Replies to post #250706 on Biotech Values

[Mufaso]

NT-0796 as an oral once daily "inhibitor of the NLRP3 inflammasome" for obesity looks like a very interesting NME in addition to its promise in nuero indications. (I will add it to the ORAL weight loss candidates in the next few days.)

Their phase 1 press release stated:

Overall, NT-0796 was safe and well tolerated and no drug-related liver function test (LFT) abnormalities were observed.

https://www.nodthera.com/news/nodthera-announces-positive-phase-1-study-readouts-for-the-nlrp3-inflammasome-inhibitors-nt-0796-and-nt-0249/

I'm a bit surprised by this new MOA that is not a "hormone" or GLP1 based approach . Another company I'd like to invest in but can't because it is private. Certainly big pharma is looking at this one as well as an acquisition.